Skip to main content
SpringerLink
Log in

Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Octreotide and lanreotide, the first-generation somatostatin analogs, successfully control hormone hyperproduction, and related syndromes, in patients with acromegaly and neuroendocrine tumors. However, their anti-tumor effect, rather evident in large number of pituitary adenomas in acromegalic patients, has been hypothesized for a long time in patients with neuroendocrine tumors as well, although a significant tumor shrinkage has rarely been observed. However, the recent publication of the CLARINET study has strengthened the evidence, already emerged with the PROMID trial, that the long-term treatment with the first-generation long-acting somatostatin analogs may exert an anti-tumor activity on G1 and G2 enteropancreatic neuroendocrine tumors, as well. After the publication, majority of international guidelines have updated their algorithms in line with these results and this class of drugs obtained the indication as anti-tumor agents in the majority of patients with neuroendocrine tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Strosberg J, Kvols L (2010) Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 16:2963–2970

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663

    Article  CAS  PubMed  Google Scholar 

  3. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, CLARINET Investigators (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224–233

    Article  PubMed  Google Scholar 

  4. Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Müller HH, Arnold R, PROMID Study Group (2017) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (promid): results of long-term survival. Neuroendocrinology 104(1):26–32

    Article  CAS  PubMed  Google Scholar 

  5. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P, CLARINET Investigators (2016) Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer 23:191–199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ratain MJ, Eckhardt SG (2004) Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 22:4442–4445

    Article  PubMed  Google Scholar 

  7. Maitland ML, Schwartz LH, Ratain MJ (2013) Time to tumor growth: a model end point and new metric system for oncology clinical trials. J Clin Oncol 31:2070–2072

    Article  CAS  PubMed  Google Scholar 

  8. Caplin M, Pavel M, Ruszniewski P, Liyanage N, Massien C, Dromain C (2016) Tumor growth rate (TGR) as indicator of antitumor activity of with Lanreotide Autogel/Depot (LAN) versus Placebo (Pbo) in intestinal/pancreatic NET: post hoc analysis of CLARINET data. In: Abstract book 13th ENETS Conference, Barcelona

  9. Grande E, Martínez-Sáez O, Gajate-Borau P, Alonso-Gordoa T (2017) Translating new data to the daily practice in second line treatment of renal cell carcinoma: the role of tumor growth rate. World J Clin Oncol 8:100–105

    Article  PubMed  PubMed Central  Google Scholar 

  10. Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R, Ferolla P, et al (2016) Safety of high doses lanreotide treatment in patients with progressive neuroendocrine tumors: results from a prospective phase II trial. In: Abstract book 13th ENETS Conference, Barcelona

  11. Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D (2015) Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol 21:1945–1955

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ferolla P, Faggiano A, Grimaldi F, Ferone D, Scarpelli G, Ramundo V, Severino R, Bellucci MC, Camera LM, Lombardi G, Angeletti G, Colao A (2012) Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest 35:326–331

    CAS  PubMed  Google Scholar 

  13. Appetecchia M, Baldelli R (2010) Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 29:19

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K (2015) Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Dev Ther 9:5075–5086

    Article  Google Scholar 

  15. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E, NETTER-1 Trial Investigators (2017) Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135

    Article  CAS  PubMed  Google Scholar 

  16. Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A (2016) Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget 7:5538–5547

    Article  PubMed  Google Scholar 

  17. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Delle Fave G, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME, RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. RAD001 in advanced neuroendocrine tumors, Fourth Trial (RADIANT-4) study group. Lancet 387:968–977

    Article  CAS  PubMed  Google Scholar 

  18. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC, RADIANT-2 Study Group (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. RADIANT-2 Study Group. Lancet 378:2005–2012

    Article  CAS  PubMed  Google Scholar 

  19. Berardi R, Morgese F, Torniai M, Savini A, Partelli S, Rinaldi S, Caramanti M, Ferrini C, Falconi M, Cascinu S (2016) Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol 8:389–401

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kaltsas G, Grossman AB (2015) The expanding role of somatostatin analogues in the treatment of neuroendocrine tumours: the CLARINET study. Clin Endocrinol 83:759–761

    Article  Google Scholar 

  21. Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K, Vienna Consensus Conference participants (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2):172–185

    Article  CAS  PubMed  Google Scholar 

  22. Kulke MH et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw 13(1):78–108

    Article  CAS  Google Scholar 

  23. Kulke MH et al (2017) NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine tumors, version 2.2017. http://www.nccn.org. Accessed 12 May 2017

Download references

Acknowledgements

The authors acknowledge all the other people involved in the tumor board and management of patients with neuroendocrine tumors at IRCCS Policlinico San Martino, University of Genova. This paper was partially supported by Grants from MIUR (2002067251-001), the University of Genova, and from Fondo per gli Investimenti della Ricerca di Base (FIRBRBAU019TMF_001).

Author information

Authors and Affiliations

  1. Endocrinology Unit, Department of Internal Medicine (DiMI), University of Genova, Genoa, Italy

    M. Albertelli, E. Nazzari, E. Ambrosetti & D. Ferone

  2. Medical Oncology Unit, IRCCS Policlinico San Martino, Genoa, Italy

    S. Sciallero

  3. Pathology unit, Department of Health Science (DiSSAL), University of Genova, Genoa, Italy

    F. Grillo

  4. Nuclear Medicine Unit, Department of Health Science (DiSSAL), University of Genova, Genoa, Italy

    S. Morbelli

  5. Oncologic Surgery Unit, Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genova, Genoa, Italy

    F. De Cian

  6. Department of Radiology, IRCCS Policlinico San Martino, Genoa, Italy

    G. Cittadini

  7. Department of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy

    A. Ciarmiello

  8. Center of Excellence for Biomedical Research (CEBR), University of Genova, Genoa, Italy

    D. Ferone

Authors
  1. M. Albertelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Nazzari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Sciallero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Grillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Morbelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. De Cian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Cittadini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Ambrosetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Ciarmiello
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D. Ferone
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the IRCCS Policlinico San Martino, University of Genova Neuroendocrine Tumor Board

Corresponding author

Correspondence to D. Ferone.

Ethics declarations

Disclosure statement

The authors have nothing to disclose.

Conflict of interest

The authors declare that there is no conflict of interest with respect to the publication of this article.

Informed consent

Informed consent was not applicable.

Research invovling human and animal participants

This opinion not involved human participants and/or animals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albertelli, M., Nazzari, E., Sciallero, S. et al. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. J Endocrinol Invest 40, 1265–1269 (2017). https://doi.org/10.1007/s40618-017-0692-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-017-0692-0

Keywords

Search

Navigation